Literature DB >> 19017561

Congenital myasthenic syndromes.

Joseph H Nogajski1, Matthew C Kiernan, Robert A Ouvrier, P Ian Andrews.   

Abstract

Congenital myasthenic syndromes (CMS) are a heterogeneous group of uncommon, inherited disorders affecting the neuromuscular junction. The defects interfere with presynaptic, synaptic, or postsynaptic function and compromise neuromuscular transmission. Most patients with CMS have similar clinical features regardless of the underlying defect, but attention to clinical and electrodiagnostic parameters can narrow the diagnostic spectrum. Recent advances in our understanding of the cellular mechanisms underlying specific syndromes allow DNA testing for some forms of CMS. Diagnosis of CMS enables a rationale for management to be developed. Two cases of genetically determined CMS as well as an undiagnosed infant are presented to highlight the clinical and electrophysiological difficulties associated with the diagnosis and management of such syndromes.

Entities:  

Mesh:

Year:  2008        PMID: 19017561     DOI: 10.1016/j.jocn.2008.05.001

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  8 in total

1.  An ocular motility conundrum.

Authors:  Elizabeth Margaret McElnea; Kirk Stephenson; Bernie Lanigan; Ian Flitcroft
Journal:  BMJ Case Rep       Date:  2014-10-27

2.  Phenotypic heterogeneity in a large Thai slow-channel congenital myasthenic syndrome kinship.

Authors:  Rawiphan Witoonpanich; Teeratorn Pulkes; Charungthai Dejthevaporn; Praphan Yodnopklao; Pirada Witoonpanich; Suppachok Wetchaphanphesat; Joan M Brengman; Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-03       Impact factor: 4.296

3.  Delayed diagnosis of congenital myasthenia due to associated mitochondrial enzyme defect.

Authors:  Yiran Guo; Minal J Menezes; Manoj P Menezes; Jinlong Liang; Dong Li; Lisa G Riley; Nigel F Clarke; P Ian Andrews; Lifeng Tian; Richard Webster; Fengxiang Wang; Xuanzhu Liu; Yulan Shen; David R Thorburn; Brendan J Keating; Andrew Engel; Hakon Hakonarson; John Christodoulou; Xun Xu
Journal:  Neuromuscul Disord       Date:  2014-12-10       Impact factor: 4.296

Review 4.  Ephedrine for myasthenia gravis, neonatal myasthenia and the congenital myasthenic syndromes.

Authors:  Charlotte Vrinten; Angeli M van der Zwaag; Stephanie S Weinreich; Rob J P M Scholten; Jan J G M Verschuuren
Journal:  Cochrane Database Syst Rev       Date:  2014-12-17

5.  Induced formation and maturation of acetylcholine receptor clusters in a defined 3D bio-artificial muscle.

Authors:  Lin Wang; Janet Shansky; Herman Vandenburgh
Journal:  Mol Neurobiol       Date:  2013-01-31       Impact factor: 5.590

6.  Molecular control of neuromuscular junction development.

Authors:  Elisabetta Ferraro; Francesca Molinari; Libera Berghella
Journal:  J Cachexia Sarcopenia Muscle       Date:  2011-10-14       Impact factor: 12.910

7.  CHRNE compound heterozygous mutations in congenital myasthenic syndrome: A case report.

Authors:  Kunfang Yang; Hongyi Cheng; Fang Yuan; Linyi Meng; Rongrong Yin; Yuanfeng Zhang; Simei Wang; Chunmei Wang; Yanfen Lu; Jiaming Xi; Qin Lu; Yucai Chen
Journal:  Medicine (Baltimore)       Date:  2018-04       Impact factor: 1.889

8.  Variants in SLC18A3, vesicular acetylcholine transporter, cause congenital myasthenic syndrome.

Authors:  Gina L O'Grady; Corien Verschuuren; Michaela Yuen; Richard Webster; Manoj Menezes; Johanna M Fock; Natalie Pride; Heather A Best; Tatiana Benavides Damm; Christian Turner; Monkol Lek; Andrew G Engel; Kathryn N North; Nigel F Clarke; Daniel G MacArthur; Erik-Jan Kamsteeg; Sandra T Cooper
Journal:  Neurology       Date:  2016-09-02       Impact factor: 9.910

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.